E-mail this image
New drugs show promise in treating deadly melanoma
PLX4032, or vemurafenib, is the first chemotherapy agent directed at a specific mutation involved in the formation of skin tumors, which occurs in about half of melanoma patients. Ipilimumab, marketed as Yervoy, stimulates the immune system to fight tumors, and has proven to be more effective than both conventional chemotherapy and a vaccine used to treat melanoma. Researchers reported the findings on June 5 at a meeting of the American Society of Clinical Oncology.